CARVYKTI® (ciltacabtagene autoleucel) logo
  • About CARVYKTI®
    How CARVYKTI® works
    Manufacturing CARVYKTI®
  • Cartitude-4 Efficacy
    Primary Analysis
    Study Design
    Progression-Free Survival (PFS)
    Overall Survival (OS)
    Depth of Response
    Duration of Response
    Follow-Up Analysis
    Progression-Free Survival (PFS)
    Overall Survival (OS)
    Depth of Response
    Duration of Response
  • CARVYKTI® Safety
    Boxed Warning
    Cytokine Release
    Syndrome (CRS)
    Neurologic Toxicities
    Hemophagocytic
    Lymphohistiocytosis (HLH)
    Prolonged and/or
    Recurrent Cytopenias
    Secondary Malignancies
    Additional Warnings & Precautions, and ARs ≥10%
    Long-Term Safety
  • TREATMENT PROCESS
    Patient Eligibility
    Steps in the Treatment Process
  • Resources
    For Physicians
    For Nurses/APPs
    For Patients/Care Partners
    Patient Support Program
    For Access and Reimbursement Support
    For Order Management
  • Additional Trials
    Cartitude-1 Efficacy
    Study Design
    Depth of Response
    Duration of Response
    Survival Rates
    Time to Response
  • Unmet Need
  • Treatment Centers
  • Coverage Lookup
  • Get In Touch
  • CARVYKTI® Prescribing Information
  • CARVYKTI® REMS
  • Contact Us
  • Go To Patient Website
  • Prescribing Information
    CARVYKTI® PRESCRIBING INFORMATION
    CARVYKTI® LA INFORMACIÓN DE PRESCRIPCIÓN
  • CARVYKTI® REMS
  • Get In Touch
  • Contact Us
  • For US Healthcare Professionals
  • Go To Patient Website
Treatment CentersCoverage Lookup

Site map

  • Home
  • About CARVYKTI®

    • How CARVYKTI® works
    • Manufacturing CARVYKTI®
  • CARTITUDE-4 Efficacy
    • Primary Analysis
      • Study design
      • Progression-free survival (PFS)
      • Overall survival (OS)
      • Depth of response
      • Duration of response
    • Follow-Up Analysis
      • Progression-free survival (PFS)
      • Overall survival (OS)
      • Depth of response
      • Duration of response
  • CARVYKTI® Safety
    • Boxed Warning
    • Cytokine release syndrome (CRS)
    • Neurologic toxicities
    • Hemophagocytic lymphohistiocytosis (HLH)
    • Prolonged and/or recurrent cytopenias

    • Secondary malignancies

    • Additional warnings & precautions, and ARs ≥10%
    • Long-term safety
  • Treatment Process
    • Patient eligibility
    • Steps in the treatment process

  • Resources
    • For physicians
    • For nurses/APPs
    • For patients/care partners
    • Patient support program
    • For access and reimbursement support
    • For order management
  • Additional Trials
    • CARTITUDE-1 Efficacy

      • Study design
      • Depth of response
      • Duration of response
      • Survival rates
      • Time to response
  • Unmet Need
  • Treatment Centers
  • Coverage Lookup
  • Get in Touch
  • Prescribing Information

  • CARVYKTI® REMS

  • Contact Us
  • Cookie Policy
  • Privacy Policy
  • Legal Notice

GET IN
TOUCH

SCROLL TO TOP ↑